Weight loss is not a vanity metric
[] The GIPR antagonist SKL-14959 decreases the BW gain, BMI, HbA1c, fasting glucose, and triacylglycerol contents in the liver compared with vehicle vehicle-treated group in a mice model of obesity
Clinical trial experiencesummarized by the FDA mantra what you study is what you getdirectly dictates which doses, their timing, and delivery devices receive approval, often limiting the ability to individualize treatment
Key Takeaways A less expensive, generic version of the GLP-1 medication Victoza is coming to market Hopefully, the approval will help prevent shortages triggered by demand for injectable weight loss drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) There is still no generic version of Ozempic THURSDAY, Dec